Thomas B. Smith - 10 Feb 2026 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
EVP and Chief Medical Officer
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Thomas B. Smith, MD
Issuer symbol
COLL
Transactions as of
10 Feb 2026
Net transactions value
-$815,086
Form type
4
Filing time
12 Feb 2026, 16:30:19 UTC
Previous filing
03 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Thomas B EVP and Chief Medical Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON /s/ Colleen Tupper as Attorney-In-Fact For Thomas B. Smith, MD 12 Feb 2026 0001748462

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Award $0 +14,268 +20% $0.000000 85,312 10 Feb 2026 Direct F1, F2
transaction COLL Common Stock Award $0 +22,774 +27% $0.000000 108,086 10 Feb 2026 Direct F3
transaction COLL Common Stock Tax liability $275,685 -5,897 -5.5% $46.75 102,189 10 Feb 2026 Direct F4
transaction COLL Common Stock Tax liability $539,402 -11,538 -11% $46.75 90,651 10 Feb 2026 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2 Includes 376 and 404 shares acquired on July 18, 2025 and January 16, 2026, respectively, under the Issuer's employee stock purchase plan.
F3 Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 22,774 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
F4 Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
F5 Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.